Central Montana Medical Center has broken ground on a $15.6 million cancer center that will bring comprehensive cancer care services to central Montana. That means residents living in central and northern Montana won’t have to travel as long for cancer treatment.
University of Montana working on vaccine for fentanyl, heroin overdose
A vaccine to prevent overdosing on fentanyl and one for heroin are in the works at the University of Montana and partner institutions. Human trials are expected to start in early 2024 for both vaccines, according to UM.
UM receives $8 million grant to benefit the L.S. Skaggs Institute for health innovation
Only three years after its creation, the University of Montana and University of Montana Foundation today announced a significant investment to benefit the L.S. Skaggs Institute for Health Innovation. Known as SIHI, the institute will use this investment to expand its influence as a statewide hub for health education, research and outreach — with a goal of improving access to emerging health innovations for all Montanans.
Montana State announces eighth class of Hilleman Scholars
Fifty-three high school graduates from across Montana have been selected for their effort and potential as the eighth class of Montana State University’s Hilleman Scholars Program, which is named after Maurice Hilleman, one of the state’s most influential native sons and an MSU graduate.
‘Keeps us going’: Crow nonprofit gets $180K grant for health equity
In July, Genentech, a biotechnology company, awarded a $180,000 unrestricted grant to Messengers for Health to promote health equity.
Solo-Dex Nominated for Prestigious 2023 Prix Galien USA Awards
The Galien Foundation has recognized the significant contributions of the Wolf Creek, MT company in the “Best Medical Technology” category.
Inimmune Announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004
Milestone marks transition of Inimmune Corporation to a clinical-stage company.
New Diagnostic Tests Could Change Leukemia Prevention and Treatment
A Montana based molecular diagnostic company, Alercell Inc., is pioneering novel techniques to augment the way leukemia is diagnosed, treated and ultimately prevented.
Solo-Dex, Inc. Strikes Groundbreaking Agreement for Distribution in Saudi Arabia of its Fascile(R) Non-Opioid Acute Pain Management Suite
Wolf Creek company Solo-Dex, a leading player in the development, manufacture, and sales of innovative non-opioid acute pain management solutions, is pleased to announce a strategic master distribution agreement with CH Trading Group LLC and Farouk, Maamoun Tamer & Co. This groundbreaking partnership will pave the way for the distribution of Solo-Dex’s revolutionary Fascile® suite of products within the Kingdom of Saudi Arabia.
Alercell celebrates National Cancer Survivors’ Day® 2023
The National Cancer Survivors’ Day Foundation invites all cancer survivors to celebrate on June 4 and Alercell joins all survivors to celebrate another beautiful day of life. The date marks the 36th annual Celebration of Life.